Pieris Pharmaceuticals Gmbh

Sanofi

Morphosys Ag

Daiichi Sankyo Company, Limited

F. Hoffmann-la Roche Ag

Hoffmann-la Roche Inc.

Les Laboratoires Servier

Christine Rothe

Andrea Allersdorfer

Marlon Hinner

Alexander Wiedenmann

Rachida Siham Bel Aiba

Shane Olwill

Bradley Lunde

Jochen Kruip

Kristian Hobolt Jensen

Carsten Corvey

Laurent Fraisse

Martin Hülsmeyer

Astrid Rey

Michael Mourez

Heike Stump

Bernhard Calandra

Nathalie Karst

Tohru Takahashi

Ryuji Hashimoto

Gabriele Matschiner

Timo Eichner

Michael Otto Bardroff

Bernd Bohrmann

Walter Huber

Manfred Brockhaus

Hansruedi Loetscher

Corinna Löhning

Titus Kretzschmar

Corinna Schlosser

Christer Nordstedt

Shinji Yamaguchi

Andreas Hohlbaum

Christian Lange

Laurent Audoly

Futoshi Nara

Ingo Focken

Kazufumi Kubota

Hendrik Gille

Hans-Falk Rasser

Mamoru Otoyo

Tomohiro Nishizawa

Sakiko Takahashi

Mitsuhiro Makino

Takahide Aburatani

Chikako Nagasaki

Dorothea Rat

Marina Pavlidou

Thomas Stuedemann

Juergen Schaefer

Bernard Calandra

Josef Prassler

Stefanie Urlinger

Markus Enzelberger

Ulrich Moebius

Stefanie Thiel

Rachida Bel Aiba

Thomas Jean Jaquin

Janet Peper

Lucia Pattarini

Alix Scholer-Dahirel

Corinna Loehning

The present disclosure provides human lipocalin muteins that bind CD137 and can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure also concerns methods of making CD137 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

Proteins specific for CD137

The disclosure provides a fusion polypeptide specific for both CD137 and GPC3, which fusion polypeptide can be useful for directing CD137 clustering and activation to GPC3-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.

Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)

The present disclosure provides human tear lipocalin muteins that specifically bind to LAG-3, which can be used in pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as cancer, infectious diseases, and autoimmune diseases. The present disclosure further shows the human lipocalin muteins can inhibit the binding of LAG-3 to MHC class II on cells overexpressing MHC class II. The present disclosure also concerns methods of making LAG-3 binding lipocalin muteins described herein as well as compositions comprising such lipocalin muteins. The present disclosure further relates to nucleic acid molecules encoding such lipocalin muteins and to methods for generation of such lipocalin muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these lipocalin muteins as well as compositions comprising one or more of such lipocalin muteins.

Lipocalin muteins with binding affinity for LAG-3

The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)

The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.

Proteins specific for calcitonin gene-related peptide

The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth ofand/or to prevent or treatbiofilm infection as well as diseases or disorders associated withbiofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.

Fusion molecules

Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response

Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptides

The disclosure provides a fusion polypeptide specific for both CD137 and HER2/neu, which fusion polypeptide can be useful for directing CD137 clustering and activation to HER2/neu-positive tumor cells. Such fusion polypeptide can be used in many pharmaceutical applications, for example, as anti-cancer agents and/or immune modulators for the treatment or prevention of human diseases such as a variety of tumors. The present disclosure also concerns methods of making the fusion polypeptide described herein as well as compositions comprising such fusion polypeptide. The present disclosure further relates to nucleic acid molecules encoding such fusion polypeptide and to methods for generation of such fusion polypeptide and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of such fusion polypeptide as well as compositions comprising one or more of such fusion polypeptides.

Anti-cancer fusion polypeptide

Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof

Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof

The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.

Proteins specific for pyoverdine and pyochelin

Growing community of inventors

Dachau, Germany

Christine Rothe